Evidence map›Paper›PMID 36531670›Full record

ArticleResearch and practice in thrombosis and haemostasis2023

Immune thrombocytopenia and COVID-19 vaccination: Outcomes and comparisons to prepandemic patients.

Philip Young-Ill Choi, Danny Hsu, Huyen Anh Tran, Chee Wee Tan, Anoop Enjeti, Vivien Mun Yee Chen, Eileen Merriman, Agnes S M Yong, Jock Simpson, Elizabeth Gardiner and 4 more

Open access · goldAbstract read
PubMed Full text at PMC Publisher
In one paragraph

Article in Research and practice in thrombosis and haemostasis, 2023. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 4 papers.

0numbers the graph read from it
0cells of the map it votes in
4citing papers in PubMed
1.5field-weighted citation impact, top 18% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

4 citing papers in PubMed, 5 citations in OpenAlex.

  1. Article
  2. Article
  3. Article
  4. COVID-19 vaccination and immune thrombocytopenia: Cause for vigilance, but not panic.Research and practice in thrombosis and haemostasis · 2023
    Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

14 authors at 11 institutions in 2 countries.

Philip Young-Ill ChoiThe Canberra Hospital, Canberra, Australian Capital Territory, Australia.
Danny HsuLiverpool Hospital (New South Wales Health Pathology), Liverpool, NSW, Australia.
Huyen Anh TranThe Alfred Hospital, Melbourne, Victoria, Australia.
Chee Wee TanRoyal Adelaide Hospital, South Australia Pathology, Adelaide, South Australia, Australia.
Anoop EnjetiCalvary Mater Hospital, Newcastle, New South Wales, Australia.
Vivien Mun Yee ChenANZAC Research Institute, University of Sydney, New South Wales, Australia.
Eileen MerrimanWaitemata District Health Board, Department of Haematology, New Zealand.
Agnes S M YongDepartment of Haematology, Royal Perth Hospital, Perth, Western Australia, Australia.
Jock SimpsonPort Macquarie Base Hospital, New South Wales, Australia.
Elizabeth GardinerJohn Curtin School of Medical Research, Australian National University, Canberra, Australian Capital Territory, Australia.
Nicolas CherbuinNational Centre for Epidemiology and Population Health, Australian National University, Canberra, Australian Capital Territory, Australia.
Jennifer CurnowWestmead Hospital, Sydney, New South Wales, Australia.
Dominic PepperellFiona Stanley Hospital (PathWest), Murdoch, Western Australia, Australia.
Robert BirdPrincess Alexandra Hospital, Brisbane, Queensland, Australia.
Australian National University · AUThe University of Sydney · AUCalvary Mater Newcastle Hospital · AUFiona Stanley Hospital · AULiverpool Hospital · AUPort Macquarie Base Hospital · AUPrincess Alexandra Hospital · AUSouth Australia Pathology · AUThe Alfred Hospital · AUThe University of Western Australia · AUWaitemata District Health Board · NZ

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

Background: Immune thrombocytopenia (ITP) has been reported following COVID-19 vaccination. After index case fatalities, there was concern among patients both with and without a prior history of ITP in Australia. Objectives: To describe treatment outcomes of ITP after COVID-19 vaccination and compare relapsed vs historical pre-COVID-19 ITP cohorts. Methods: We collected ITP cases in Australia within 6 weeks of receiving any COVID-19 vaccination as part of primary vaccination (up to October 17, 2021). Second, we reviewed platelet charts in a historical ITP cohort to determine whether platelet variability was distinct from relapsed ITP after vaccination. Results: We report on 50 patients (37 Conclusion: ITP was more frequently reported after AstraZeneca ChAdOx1 nCoV-19 than Pfizer BNT162b2 vaccination. Standard ITP treatments remain highly effective for

Indexed as

BNT162 vaccineChAdOx1 nCov-19COVID-19 vaccinesimmune thrombocytopeniatreatment outcomevaccination

Identifiers

PMID36531670
PMCPMC9744687
OpenAlexW4311928222

What OpenQuestion holds

Textmetadata
LicenceCC BY-NC-ND
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.